La chaîne d'options affiche les données clés des options sur actions de Biodexa Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Biodexa Pharmaceuticals..

Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock, Chaîne d'Options

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Press Releases

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in  Familial Adenomatous Polyposis (FAP)

ADR Ratio Change

News

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change Effective

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial  in Familial Adenomatous Polyposis (FAP)

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Interim results for the six months ended June 30, 2025

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

BDRX

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

BriaCell Therapeutics

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Liminatus Pharma

Oragenics

Onconetix

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Ladenburg Thalmann

Screenshot 2025-09-08 at 3.59.27 PM

Biotech

General

RXRX

Tempest Therapeutics, Inc. - Common Stock

TPST

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled

BDRX-logo

PVLA

How Biodexa Is Racing To Get Its Phase 3 Program In FAP Under Way And Gain First-Mover Advantage In A $7B Addressable Market

Screenshot 2025-06-17 at 8.31.13 PM

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Screenshot 2025-03-18 at 8.36.36 PM

Fast Track Designation Secured, Successful Protocol Discussion With FDA And CROs Confirmed, Biodexa On Track To Initiate Funded Phase 3 FAP Trial Next Quarter

Comments

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals (BDRX) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL